Seagen Inc. (NASDAQ:SGEN – Get Rating) EVP Charles R. Romp sold 319 shares of the firm’s stock in a transaction that occurred on Wednesday, April 20th. The stock was sold at an average price of $144.32, for a total transaction of $46,038.08. Following the sale, the executive vice president now directly owns 49,816 shares of the company’s stock, valued at approximately $7,189,445.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
SGEN stock traded down $3.44 during mid-day trading on Friday, reaching $138.00. The company had a trading volume of 707,861 shares, compared to its average volume of 1,072,047. The stock has a market capitalization of $25.37 billion, a P/E ratio of -37.30 and a beta of 0.83. Seagen Inc. has a one year low of $117.46 and a one year high of $192.79. The stock’s 50-day simple moving average is $138.51 and its two-hundred day simple moving average is $150.50.
Seagen (NASDAQ:SGEN – Get Rating) last posted its earnings results on Wednesday, February 9th. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.16). The company had revenue of $429.85 million during the quarter, compared to the consensus estimate of $403.42 million. Seagen had a negative net margin of 42.84% and a negative return on equity of 20.68%. During the same quarter in the previous year, the business posted $0.90 earnings per share. As a group, research analysts predict that Seagen Inc. will post -3.67 earnings per share for the current fiscal year.
A number of hedge funds have recently bought and sold shares of SGEN. Truist Financial Corp increased its holdings in shares of Seagen by 1.2% during the first quarter. Truist Financial Corp now owns 17,337 shares of the biotechnology company’s stock valued at $2,498,000 after purchasing an additional 210 shares during the period. Louisiana State Employees Retirement System increased its holdings in shares of Seagen by 1.0% during the first quarter. Louisiana State Employees Retirement System now owns 9,800 shares of the biotechnology company’s stock valued at $1,410,000 after purchasing an additional 100 shares during the period. Xponance Inc. increased its holdings in shares of Seagen by 1.1% during the first quarter. Xponance Inc. now owns 13,865 shares of the biotechnology company’s stock valued at $1,997,000 after purchasing an additional 153 shares during the period. Ellevest Inc. increased its holdings in shares of Seagen by 41.1% during the first quarter. Ellevest Inc. now owns 1,633 shares of the biotechnology company’s stock valued at $235,000 after purchasing an additional 476 shares during the period. Finally, Manning & Napier Group LLC increased its holdings in shares of Seagen by 2.4% during the first quarter. Manning & Napier Group LLC now owns 957,452 shares of the biotechnology company’s stock valued at $137,920,000 after purchasing an additional 22,759 shares during the period. Institutional investors own 89.54% of the company’s stock.
About Seagen (Get Rating)
Seagen Inc, a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer.
- Get a free copy of the StockNews.com research report on Seagen (SGEN)
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
- Should You Buy Carvana or AutoNation or Pass on Both?
Receive News & Ratings for Seagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seagen and related companies with MarketBeat.com's FREE daily email newsletter.